Holen Sie sich die Stockscreener-App
66.53
0.15%
0.10
Schlusskurs vom Vortag:
$66.43
Offen:
$65.785
24-Stunden-Volumen:
2.30M
Relative Volume:
1.08
Marktkapitalisierung:
$12.88B
Einnahmen:
$3.29B
Nettoeinkommen (Verlust:
$268.74M
KGV:
48.55
EPS:
1.3704
Netto-Cashflow:
$759.12M
1W Leistung:
+2.88%
1M Leistung:
+9.57%
6M Leistung:
+10.09%
1J Leistung:
+17.23%
1-Tages-Spanne:
$65.52
$66.64
1-Wochen-Bereich:
$64.33
$67.69
52-Wochen-Spanne:
$49.26
$70.98
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
66.53 | 13.10B | 3.29B | 268.74M | 759.12M | 1.3704 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Fortgesetzt | Morgan Stanley | Overweight |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-20 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | Herabstufung | Stifel | Buy → Hold |
| 2025-09-08 | Eingeleitet | H.C. Wainwright | Neutral |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-24 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
Weekly Buzz: RARE, REGN Secure FDA Nod, BMRN Stikes Deal; HUMA, EYPT Face Trial Setbacks - RTTNews
NFJ Investment Group LLC Takes Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
40,919 Shares in BioMarin Pharmaceutical Inc. $BMRN Bought by Paralel Advisors LLC - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Raised to "Strong-Buy" at BMO Capital Markets - MarketBeat
Eagle Health Investments LP Acquires Shares of 624,676 BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Edmond DE Rothschild Holding S.A. Purchases Shares of 687,030 BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Boehringer again rises up rare disease reputation rankings - Fierce Pharma
Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today - Yahoo Finance
BioMarin Pharmaceutical (BMRN)’s Alesta Deal Adds New Growth Potential in Rare Diseases - Yahoo Finance
BMRN Looks 16.4% Undervalued on GF Value™ Amid Market Concerns Over Voxzogo - GuruFocus
BioMarin initiated an outperform at BMO as Voxzogo erosion overstated - Seeking Alpha
BioMarin Pharmaceutical Market Sentiment - Benzinga France
BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment - Zacks Investment Research
BIOMARIN PHARMACEUTICAL INC. : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $98 - Bitget
Canaccord reiterates BioMarin stock rating on Alesta acquisition By Investing.com - Investing.com South Africa
H.C. Wainwright cuts BioMarin stock price target on acquisition costs By Investing.com - Investing.com South Africa
BMO Capital Markets Initiates Coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) - MarketBeat
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For We - Benzinga
BMO initiates BioMarin stock with Outperform, $98 price target By Investing.com - Investing.com South Africa
Canaccord reiterates BioMarin stock rating on Alesta acquisition - Investing.com
H.C. Wainwright cuts BioMarin stock price target on acquisition costs - Investing.com
BMRN Initiated Coverage by BMO Capital -- Rating Set at Outperform - GuruFocus
BioMarin to Acquire RTW Biotech Portfolio Company Alesta Therapeutics for Up to $490 Million - Kalkine Media
BMO initiates BioMarin stock with Outperform, $98 price target - Investing.com
BioMarin to acquire Alesta Therapeutics for up to $490 million By Investing.com - Investing.com Australia
GSA Capital Partners LLP Invests $944,000 in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
BioMarin to acquire Alesta Therapeutics for up to $490 million - Investing.com
REGRTW Biotech Opp.BioMarin to acquire Alesta Therapeutics - TradingView
BioMarin to acquire Alesta Therapeutics for $275M upfront By Investing.com - Investing.com Nigeria
BioMarin to Acquire Alesta in Cash Deal, Betting on First Oral HPP Therapy - nai500.com
BioMarin Buying Alesta Therapeutics For Up To $490M - Law360
BMRN Looks 19.4% Undervalued on GF Value™ - GuruFocus
BioMarin looks to spur growth with potential $490M buyout of Dutch bone drug company - The Business Journals
BioMarin snaps up Alesta's lead asset for $275m - pharmaphorum
BioMarin Pays $275M Upfront for Alesta to Challenge AstraZeneca in Rare Bone Disease - finance.biggo.com
BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment - Benzinga
BioMarin to Acquire Alesta Therapeutics for Up to $490 Million - citybiz
BioMarin acquires experimental drug for rare bone disorder in $275M deal - BioPharma Dive
BMRN Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
BioMarin stock surges on $275M Alesta acquisition deal By Investing.com - Investing.com Australia
HC Wainwright Has Lowered Expectations for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price - MarketBeat
M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration with Eli Lilly, Chugai and GSK Enter License Agreement for AID351 - Pharmaceutical Executive
BioMarin stock surges on $275M Alesta acquisition deal - Investing.com
BioMarin Shares Jump After $275 Million Deal to Acquire Alesta Therapeutics - Yahoo Finance
Form 8K Biomarin Pharmaceutical Inc For: 18 August By Investing.com - Investing.com Nigeria
BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca - Fierce Biotech
BioMarin Pharmaceutical to Acquire Alesta Therapeutics for up to $490 Million - marketscreener.com
BioMarin to acquire Alesta Therapeutics for $275M upfront - Investing.com
BioMarin to acquire Alesta for $275M upfront (BMRN:NASDAQ) - Seeking Alpha
BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline - PR Newswire
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):